The discovery of unique insights into pathogenic mechanisms in rheumatoid arthritis (RA) are opening up the potential for the development of novel treatments for this devastating disease. Ulrika Norin and Rikard Holmdal’s research has identified a novel drug target that is strongly linked to RA disease progression. The target is also implicated in the development and progression of other autoimmune diseases. Following the initiation of drug discovery efforts, promising compounds have been identified that are being validated in disease-relevant translational models. Discussions are ongoing with potential partners (pharma and biotech) with an interest in developing novel therapies in this important disease area.